Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ARK Space & Defense Innovation ETF (ARKX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ARK Space & Defense Innovation ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while ARK Space & Defense Innovation ETF trades at $34.71. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | ARKX | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.45 | $37.74 |
52-Week Low | $20.06 | $25.46 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
ARK Space Exploration & Innovation ETF (ARKX) trades at $34.69, up 0.81% with strong technical momentum as moving averages signal bullish sentiment. The fund captures space economy exposure through holdings like SpaceX (8.31%) and Rocket Lab (6.27%), benefiting from growing commercial space investment. Recent news highlights ARKX as an alternative to direct SpaceX investment, with the space sector reaching $500 billion in backlog.
ARKX offers diversified space economy exposure but carries higher volatility than traditional aerospace ETFs. The fund's active management strategy and focus on disruptive space tech provide growth potential, though elevated RSI levels suggest near-term overbought conditions. Key risks include SpaceX valuation concerns and sector concentration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →
